Dr. PingLi

Partner

München + 49.89.20.60.42.200

Connect

Share

Dr. Ping Li befasst sich schwerpunktmäßig mit biotechnologischen, pharmazeutischen und chemischen Patenten im Zusammenhang mit Arzneimitteln in Form von Nanopartikeln und Makromolekülen, niedermolekularen antiviralen und krebsbekämpfenden Therapien, Polymertechnologie, Chemietechnik und Lithium-Ionen-Batterietechnik. Neben der Ausarbeitung von Patententwürfen, der Ausarbeitung von Patentanmeldungen, Einspruchs- und Beschwerdeverfahren verfügt Ping über besondere Erfahrung in Angelegenheiten im Zusammenhang mit ergänzenden Schutzzertifikaten (SPCs), einschließlich der Unterstützung und Beratung von Mandanten bei der Erlangung von SPCs und der Erstellung von SPC-Portfolios in Europa. Sie hat auch Erfahrung mit IP Due Diligence, Freedom-to-Operate-Analysen und Patentvaliditätsgutachten und war an deutschen sowie grenzüberschreitenden Patentverletzungs- und Nichtigkeitsverfahren beteiligt. Dr. Li Ping kam im Mai 2008 zu Jones Day.

Sie ist Chemikerin und Strukturbiologin mit technischer Erfahrung in organischer und anorganischer Synthese, NMR-Spektroskopie (Kernspinresonanzspektroskopie), Molekularbiologie, Proteinkristallografie, Proteinexpression und -reinigung, RNA-Biochemie (Ribonukleinsäure), Virologie, Antikörper, Chromatografie, Massenspektroskopie, Elektronenmikroskopie und radioaktiver Markierung. Ihre Doktorarbeit am Max-Planck-Institut für biophysikalische Chemie führte zu mehreren von Experten begutachteten Veröffentlichungen, darunter eine Erstautorenpublikation in der Zeitschrift Science im Jahr 2007. Pings wissenschaftlicher Hintergrund ermöglicht es ihr, das Wesentliche von Erfindungen in einem breiten Spektrum von Technologiebereichen schnell zu erfassen.

Dr. Ping Li ist Mitglied des Instituts der beim Europäischen Patentamt zugelassenen Vertreter (epi), der Deutschen Patentanwaltskammer, der International Federation of Intellectual Property Attorneys und der Deutschen Vereinigung für gewerblichen Rechtsschutz und Urheberrecht (GRUR).

Erfahrung

  • Idenix enforces patent against Gilead in Germany over sofosbuvirJones Day represented Idenix Pharmaceuticals LLC (a subsidiary of Merck & Co., Inc.) in patent litigation against Gilead in Landgericht Düsseldorf in Germany over sofosbuvir, the active ingredient in Sovaldi® and Harvoni®, Gilead's blockbuster drugs for treating Hepatitis C.
  • Puma Biotechnology obtains dismissal of opposition against its European patent relating to treatment for gefitinib/erlotinib-resistant cancers and cancers with T790M EGFR mutationAfter nearly 10 years of opposition and appeal proceedings, on behalf of Puma Biotechnology, Inc., Jones Day obtained dismissal of an opposition against a European patent, which broadly covers the use of irreversible inhibitors for the treatment of gefitinib/erlotinib-resistant cancers, as well as cancers with the T790M EGFR mutation.
  • GeneoDx invests in PathoFinderJones Day represented Shanghai GeneoDx Biotech Company Limited, a subsidiary of Sinopharm Group, a leading pharmaceutical company in China, in connection with its investment in PathoFinder Holding B.V. (PFH), which is engaging in molecular diagnostics for the detection of pathogens causing an infectious disease in the Netherlands, by way of purchasing a majority stake in PFH.
  • Celgene acquired by Bristol-Myers Squibb for approximately $74 billionJones Day advised Celgene Corporation (NASDAQ: CELG) in connection with the intellectual property and technology transactions aspects of its cash-and-stock merger with Bristol-Myers Squibb (NYSE: BMY) which has an equity value of approximately $74 billion.
  • Celgene develops European patent portfolio covering protein-bound nanoparticle technology (Nab®)Jones Day represented Celgene Corporation in successfully obtaining numerous European patents relating to one of its platform technologies, namely protein-bound nanoparticles (Nab®).
  • Leading manufacturer of low ignition proclivity papers engages in European oppositionsJones Day represents a leading paper manufacturer before the European Patent Office. 
  • Stopaq defends patent for self-healing, anti-corrosion coatings in opposition brought by global competitorJones Day is advising Netherlands-based Stopaq B.V. in the defense of its patents relating to a novel anti-corrosion protection for oil and gas pipelines that provides self-healing capability before the European Patent Office.
  • Mount Sinai School of Medicine enforces patent on key biotech pharmaceutical productJones Day represented Mount Sinai School of Medicine of New York University in a multinational cross-jurisdictional patent infringement litigation against a global pharmaceutical company.
  • Stopaq develops patent portfolio relating to self-healing, anti-corrosion coatings and sealants for use on oil and gas pipelinesJones Day is advising Netherlands-based Stopaq B.V. in prosecuting its patent portfolio relating to a novel anti-corrosion protection for oil and gas pipelines that provides self-healing capability.
  • Stopaq asserts in Germany several patents against competitor involving self-healing, anti-corrosion preparations for use on oil and gas pipelinesJones Day is advising Stopaq B.V., a Netherlands-based manufacturer of corrosion protective coatings and sealants, in a multi-patent litigation against a major competitor.
  • Sunovion establishes global patent portfolio for small molecule drugs for certain CNS disorders and painJones Day assists Sunovion Pharmaceuticals Inc. in the establishment of a global patent portfolio related to small molecule drugs for the treatment of certain CNS disorders and pain.
  • Idenix establishes patent portfolio related to nucleoside analog antiviral drugsJones Day represents Idenix Pharmaceuticals, Inc. in the management and development of a patent portfolio related to nucleoside analog antiviral drugs.
    •

    December 2024 Commentary

    Unified Patent Court: First Ruling on Equivalent Infringement

    November 2024 Commentary

    UPC: Patentees No Longer Locked Out by Pre-Transitional Period National Litigations

    November 2024 Commentary

    The Unified Patent Court: Also an Attractive Jurisdiction for SMEs

    November 2024 Commentary

    Germany's Legal Privilege: What In-House Counsel Need to Know

    October 2024 Commentary

    A Rollback on Referral to the EBA Regarding Adaptation of Description

    March 2024 Alert

    Finish in Eight Months: The EPO Sets Timeline for New Accelerated Opposition Practice

    March 2024 Alert

    Unified Patent Court Publishes Its First Case Load Statistics

    February 2024 Handout

    Pocket Guide to the Unitary Patent and Unified Patent Court

    February 2024 Alert

    UPC Nullity Actions: The New Distribution Scheme Takes Shape

    December 2022 Commentary

    Co-Ownership of Patents: Are Your Co-Owned Patents Ready for the Unified Patent Court?
    Weitere Veröffentlichungen

    • December 13, 2021
      Women in IP Speaker Series: Artificial Intelligence in the Biopharma Lifecycle: U.S. and EU IP Considerations
    • June 6, 2019
      Successful claim strategies for inventions arising from product development and emerging technologies: US v. EP, AbbVie IP Day 2019
    • September 16, 2015
      Opposition Proceedings at the EPO Webinar

    Bitte beachten Sie vor dem Versenden:

    Die Informationen auf unserer Website sind für den allgemeinen Gebrauch und stellen keine Rechtsberatung dar. Der Versand dieser E-Mail ist nicht dazu bestimmt, ein Mandatsverhältnis zu begründen, und der Erhalt dieser E-Mail stellt kein Mandatsverhältnis dar. Alles, was Sie an jemanden in unserer Kanzlei senden, ist nicht vertraulich oder privilegiert, es sei denn, wir haben zugestimmt, Sie zu vertreten. Wenn Sie diese E-Mail versenden, bestätigen Sie, dass Sie diesen Hinweis gelesen und verstanden haben.